Artiva Biotherapeutics In... (ARTV)
Artiva Biotherapeutics Statistics
Share Statistics
Artiva Biotherapeutics has 24.36M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 24.36M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 1.68K |
| FTD / Avg. Volume | 0.61% |
Short Selling Information
The latest short interest is 1.12M, so 4.61% of the outstanding shares have been sold short.
| Short Interest | 1.12M |
| Short % of Shares Out | 4.61% |
| Short % of Float | 0% |
| Short Ratio (days to cover) | 18.92 |
Valuation Ratios
The PE ratio is -1.94 and the forward PE ratio is -0.88. Artiva Biotherapeutics's PEG ratio is -0.01.
| PE Ratio | -1.94 |
| Forward PE | -0.88 |
| PS Ratio | 452.15 |
| Forward PS | 116.3 |
| PB Ratio | 0.61 |
| P/FCF Ratio | -2.04 |
| PEG Ratio | -0.01 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Artiva Biotherapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 15.39, with a Debt / Equity ratio of 0.08.
| Current Ratio | 15.39 |
| Quick Ratio | 15.39 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | -0.22 |
| Debt / FCF | -0.26 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $2.82K |
| Profits Per Employee | $-657.22K |
| Employee Count | 89 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 5.29, so Artiva Biotherapeutics's price volatility has been higher than the market average.
| Beta | 5.29 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 3.96 |
| 200-Day Moving Average | null |
| Relative Strength Index (RSI) | 33.86 |
| Average Volume (20 Days) | 276.83K |
Income Statement
In the last 12 months, Artiva Biotherapeutics had revenue of 251K and earned -58.49M in profits. Earnings per share was -5.2.
| Revenue | 251K |
| Gross Profit | 251K |
| Operating Income | -67.28M |
| Net Income | -58.49M |
| EBITDA | -64.85M |
| EBIT | -67.28M |
| Earnings Per Share (EPS) | -5.2 |
Balance Sheet
The company has 40.23M in cash and 14.35M in debt, giving a net cash position of 25.88M.
| Cash & Cash Equivalents | 40.23M |
| Total Debt | 14.35M |
| Net Cash | 25.88M |
| Retained Earnings | -246.68M |
| Total Assets | 209.58M |
| Working Capital | 176.38M |
Cash Flow
In the last 12 months, operating cash flow was -55.03M and capital expenditures -642K, giving a free cash flow of -55.67M.
| Operating Cash Flow | -55.03M |
| Capital Expenditures | -642K |
| Free Cash Flow | -55.67M |
| FCF Per Share | -4.94 |
Margins
Gross margin is 100%, with operating and profit margins of -26805.58% and -23303.98%.
| Gross Margin | 100% |
| Operating Margin | -26805.58% |
| Pretax Margin | -23303.98% |
| Profit Margin | -23303.98% |
| EBITDA Margin | -25837.05% |
| EBIT Margin | -26805.58% |
| FCF Margin | -22180.88% |
Dividends & Yields
ARTV does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ARTV is $20, which is 751.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $20 |
| Price Target Difference | 751.1% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | -0.43 |
| Piotroski F-Score | 2 |